Orphan designation: Recombinant human factor IX protein modified with three point mutations (dalcinonacog alfa), Treatment of haemophilia B, 20/06/2017, Positive
Orphan designation: Marzeptacog alfa (activated), Treatment of haemophilia B, 01/04/2019, Positive
Victoza (liraglutide) supply shortage
Human medicines European public assessment report (EPAR): Brilique, ticagrelor, Peripheral Vascular Diseases;Acute Coronary Syndrome, Date of authorisation: 03/12/2010, Revision: 21, Status: Authorised
Traineeship - Frequently asked questions (FAQs)
Human medicines European public assessment report (EPAR): Ebymect, dapagliflozin,metformin, Diabetes Mellitus, Type 2, Date of authorisation: 15/11/2015, Revision: 20, Status: Authorised
Inactivated leptospire vaccine : List of nationally authorised medicinal products - PSUSA/00010813/202211
Yellow fever vaccine (live) : List of nationally authorised medicinal products - PSUSA/00003135/202212
Declaration of interests: Silvy da Rocha Dias
Human medicines European public assessment report (EPAR): Capecitabine Accord, capecitabine, Colonic Neoplasms;Breast Neoplasms;Colorectal Neoplasms;Stomach Neoplasms, Date of authorisation: 20/04/2012, Revision: 16, Status: Authorised